Clinical trial registry record

Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM

A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 3 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated February 23, 2024.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT03429543
Last registry update
February 23, 2024
Status
Completed
Phase
Phase 3
Sponsor
Boehringer Ingelheim
Enrollment
175
Countries
United States, Argentina, Brazil, Canada, China, Colombia, Germany, Israel, Mexico, Puerto Rico, Russia, South Korea, Thailand, United Kingdom
Match confidence
90%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 3
Study design
RANDOMIZED · PARALLEL · TREATMENT · DOUBLE
Evidence population
Human clinical study registration
Participants
175
Population
ALL · 10 Years to 17 Years
Duration
2018-03-20 to 2023-05-31
Intervention
Metformin; Insulin; Placebo; Linagliptin; Empagliflozin
Comparator
Placebo - DINAMOᵀᴹ & DINAMOᵀᴹ Mono
Outcomes measured
Change in Glycated Haemoglobin (HbA1c) (%) From Baseline to the End of 26 Weeks - DINAMOᵀᴹ — Baseline (Day 1) and week…; Percentage of Patients With Treatment Failure up to or at Week 26 — Up to 26 weeks.; Change in HbA1c (%) From Baseline to the End of 26 Weeks - DINAMOᵀᴹ Mono — Baseline (Day 1) and week 26 of treatment.; Time to Treatment Failure — Up to 395 days.; Change in Fasting Plasma Glucose (FPG, mg/dL) From Baseline to the End of 26 Weeks — Baseline (Day 1) and week 26.; Change in Body Weight (kg) From Baseline to the End of 26 Weeks — Baseline (Day 1) and week 26.; Change in Systolic Blood Pressure (SBP, mmHg) From Baseline to the End of 26 Weeks — Baseline (Day 1) and week 26.; Change in Diastolic Blood Pressure (DBP, mmHg) From Baseline to the End of 26 Weeks — Baseline (Day 1) and week 26.; Percentage of Patients Who Achieve HbA1c <6.5% at the End of 26 Weeks — Baseline (Day 1) and week 26.; Percentage of Patients Who Achieve HbA1c <7.0% at the End of 26 Weeks — Baseline (Day 1) and week 26.
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 3A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 90% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Metformin · 90%Summary contains controlled topic terminology. Source terminology contains a controlled topic term.

Automated source check 100% · update recency 65%. These figures help sort records; they are not medical ratings.

metformin
Read the original source →Export JSON